US Drug Pricing Debate: Finding some dearly needed real solutions

( /-/media/files/publications/public/us_drug_pricing_debate_pc.pdf?la=en )


> Download ( /-/media/files/publications/public/us_drug_pricing_debate_pc.pdf?la=en )

Over the last few years, the pharmaceutical industry has faced a barrage of criticisms over the pricing of its prescription drugs in the United States. Public concern has generally been focused on two areas:

  • The high cost of new specialty drugs, such as for oncology and hepatitis.
  • Price increases for particularly older, often already off-patent drugs, such as the frequently mentioned cases of Turing and Valeant.

It’s important for patients and the industry that these pricing issues are resolved. Read the article for a few proposed solutions.


About the Expert





Ed Schoonveld is a Managing Principal at ZS and is the leader of the firm’s Value and Access solution area. In this role, he provides strategic consulting and research solutions to healthcare industry clients. He is considered to be one of the world’s leading experts on global pharmaceutical pricing and market access and has unparalleled experience as head of global market access and pricing functions at Wyeth, Lilly, and BMS, and as a consulting leader at Cambridge/IMS and a number of other organizations.





Bill Coyle is a ZS Associates principal and leader of the firm’s European region. He focuses on sales and marketing issues in the pharmaceutical and biotechnology industries. Bill’s areas of specialty include market access and pricing, key account management, commercial organization design, and sales effectiveness.





Howard Deutsch is a ZS Associates principal and global leader of the firm’s managed care strategy practice. He helped clients with a spectrum of sales force and marketing issues, with a particular focus on US managed-care and market access strategy.